Clinical trials: Schizoaffective Disorder
Catatonia, Schizophrenia
Personalized Prospective Study Evaluation of the Efficacy and Safety of Noninvasive Neuromodulation of TMS in Subjects With Catatonia
Evaluation effectiveness and safety of TMS in subjects with catatonia
- Conditions
- Catatonia, Schizophrenia, Schizo Affective Disorder, Bipolar Affective Disorder
- Trial name
- RECATA (NCT06176456)
- Testing
- rTMS
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Moscow Psychiatric Hospital No. 1 Named after N.A. Alexeev
Schizophenia Disorder, Schizoaffective Disorder
Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness (R33)
This randomized clinical trial will test a new technology-supported blended intervention, mobile Social Interaction Therapy by Exposure (mSITE), that targets social engagement in consumers with serious mental illness.
- Trial name
- NCT06865937
- Testing
- Mobile Intervention for Social Recovery in Serious Mental Illness (mSITE), Supportive Contact (SC)
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- University of California, San Diego
Schizophrenia, Schizo-affective Disorder
Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant
The study will be a 6-month, open-label, multiple center study in approximately 50 stable subjects diagnosed with schizophrenia or schizoaffective disorder to evaluate the safety, tolerability, and pharmacokinetics of Risperidone…
- Trial name
- NCT02658357
- Testing
- Risperidone Implant
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Braeburn Pharmaceuticals
Schizophrenia, Schizoaffective Disorder
Serotonin 1A Agonists and Cognition in Schizophrenia
Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with antipsychotic medications.
- Trial name
- NCT00178971
- Testing
- adjunctive treatment with buspirone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Northwestern University
Schizophrenia, Schizoaffective Disorder
Motivational Negative Symptoms in Schizophrenia: Intervention and Biomarkers
Negative symptoms significantly interfere with daily functioning among individuals with schizophrenia. They are strongly related to functional impairments [1] and contribute to the poor community outcomes of Veterans with…
- Trial name
- NCT02386605
- Testing
- Motivational Interviewing and Cognitive Behavioral Therapy, Relaxation Skills
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder
The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine. A secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine.
- Trial name
- NCT06319170
- Testing
- Olanzapine Extended Release, Olanzapine Immediate Release
- Where
- 5 sites in United States
- Volunteers
- 106 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Schizophrenia
Cognitive Behavioral Social Skills Training for Improving Social Functioning in People With Schizophrenia
This study evaluated the effectiveness of Cognitive Behavioral Social Skills Training versus goal-focused supportive contact in improving social functioning in people with schizophrenia.
- Trial name
- NCT00338975
- Testing
- Cognitive Behavioral Social Skills Training (CBSST), Goal-focused supportive contact (GFSC), Social Skills Training
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- Veterans Medical Research Foundation
Bipolar I Disorder, Bipolar II Disorder
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
The goal of this clinical trial is to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss, and to study the effect of individualized guided medication in…
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity
- Trial name
- OBOE-Mayo (NCT07213466)
- Testing
- Group Therapy Program, semaglutide, Phentermine-Topiramate
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Schizophrenia, Schizoaffective Disorder
Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder
The objective of the study is to evaluate the efficacy of Pramipexole, Minocycline and Aspirin compared to placebo, as add-on to anti-psychotics in the treatment of patients with schizophrenia.
- Trial name
- MAP-S-01 (NCT01320982)
- Testing
- minocycline, pramipexole, acetylsalicylic acid
- Where
- 14 sites in Israel, Romania
- Volunteers
- 400 people
- Sponsor
- Sheba Medical Center
Schizophrenia, Schizoaffective Disorder
A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to assess the time for patients to relapse when switched from an oral antipsychotic to one of two doses of long-acting risperidone injection (shots).
- Trial name
- NCT00297388
- Testing
- Risperidone, long-acting injectable
- Volunteers
- 40 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
Antipsychotic Effects on Brain Function in Schizophrenia
The purpose of the study is to determine whether two commonly-prescribed antipsychotic medications (aripiprazole and risperidone) have different effects on brain function and cognition in schizophrenia patients.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- APD (NCT01913327)
- Testing
- Aripiprazole, Risperidone, Modafinil
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, San Francisco
Schizophrenia, Schizoaffective Disorder
Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia
In this trial, researchers aim to investigate if prolonged-release melatonin can facilitate the withdrawal of chronic benzodiazepine administration in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Affective Disorder
- Trial name
- SMART (NCT01431092)
- Testing
- Melatonin
- Where
- Denmark
- Volunteers
- 86 people
- Sponsor
- Lone Baandrup
Psychosis
The Family Cognitive Adaptation Training Manual: A Test of Effectiveness
The purpose of this study is to examine the effectiveness of family cognitive adaptation training, including its impact on functioning and caregiver burden.
- Trial name
- NCT01768000
- Testing
- Family Cognitive Adaptation Training
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Psychotic Disorders
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity.
- Conditions
- Schizophrenia, Psychotic Disorders, Bipolar Disorder
- Trial name
- NCT00044187
- Testing
- Sibutramine
- Where
- 16 sites in United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia
This study will determine the comparative effectiveness of two systems designed to improve medication adherence in people with schizophrenia.
- Trial name
- NCT00406718
- Testing
- Med-eMonitor, PharmCAT, Treatment as Usual
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia Agitation, Schizo Affective Disorder
Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder
An open-label, randomized, active control inpatient trial to evaluate the efficacy and tolerability of sublingual dexmedetomidine for the treatment of agitation in inpatients with schizophrenia or bipolar disorder as measured by…
- Conditions
- Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
- Trial name
- NCT06093451
- Testing
- Dexmedetomidine, Lorazepam 2 MG/ML
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Temple University
Schizophrenia, Schizoaffective Disorder
Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
The purposes of this study are to determine: The effectiveness of olanzapine as compared to quetiapine in treating and preventing the recurrence of a variety of symptoms of schizophrenia and schizoaffective disorder in patients…
- Trial name
- NCT00090012
- Testing
- Olanzapine, Quetiapine
- Where
- 25 sites in United States
- Volunteers
- 340 people
- Sponsor
- Eli Lilly and Company
Bipolar Disorder
A Pharmacokinetic Study of Risperidone and Topiramate Administered Alone and in Combination in Patients With Bipolar Disorder or Schizoaffective Disorders
The purpose of this study is to assess the potential pharmacokinetic (absorption, distribution and excretion of the drug by the body) interaction between, and the safety of, topiramate and risperidone administered in combination…
- Trial name
- NCT00986336
- Testing
- topiramate, risperidone
- Volunteers
- 56 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to assess the maintenance of antipsychotic efficacy and safety of risperidone long-acting injectable (RLAI) in patients with schizophrenia (psychiatric disorder with symptoms of emotional instability…
- Trial name
- NCT01888107
- Testing
- Risperidone Long-acting Injectable (LAI) 25 mg, Risperidone LAI 37.5 mg, Risperidone LAI 50 mg
- Volunteers
- 347 people
- Sponsor
- Janssen-Cilag S.p.A.
Schizophrenia, Schizoaffective Disorder
Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia
The investigators would like to know the association of gene polymorphisms and metabolic adversities in clozapine-treated patients with schizophrenia in Taiwan.
- Trial name
- NCT01324167
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Taipei Medical University WanFang Hospital